EGFR and non-small cell lung carcinoma: So far, there has been no study or clinical trial evaluating the therapeutic effect of the combination of MERTK inhibitors and anti-PD-1/PD-L1 agents in NSCLC, especially in patients with TKI-sensitive EGFR mutations.